Answers are grounded in this paper and cite their sources.
To characterize the clinical profile of Shenshu granules (SG) in patients with pyelonephritis and evaluate their effectiveness in reducing the recurrence of pyelonephritis. This retrospective cohort study included patients diagnosed with pyelonephritis in Xiamen between January 1, 2013, and December 31, 2023. To minimize potential selection bias, propensity score matching (PSM) was performed at a 1:2 ratio between the observation group and the control group. A total of 5,628 patients were initially enrolled in this study. After PSM, 1,110 patients were included in the final analysis: 740 in the antibiotic-only (AO) group and 370 in the antibiotics combined with SG group. Within six months of follow-up, recurrence occurred in 85 patients (23.0%) in the SG group and 247 patients (33.4%) in the AO group, representing a significantly lower recurrence rate in the SG group ( p <0.001). Among patients who experienced recurrence within six months, 49 of 85 patients (57.6%) in the SG group and 109 of 247 patients (44.1%) in the AO group achieved therapeutic efficacy. Overall treatment effectiveness was significantly higher in the SG group than in the AO group (90.2% vs. 81.4%, p <0.001). SG demonstrated favorable therapeutic efficacy and may help alleviate symptoms, promote faster recovery, and reduce the risk of pyelonephritis recurrence when used as an adjunct to antibiotic therapy. These findings support the clinical potential of SG and warrant further investigation in larger prospective studies.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: